Dr. Mozaffar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 S Manchester Avenue Ste 110
UCI Medical Center
Orange, CA 92868Phone+1 714-456-2332Fax+1 714-456-5997
Summary
- Dr. Tahseen Mozaffar is a Professor of Neurology and Pathology and Laboratory Medicine and Vice Chair for Research in the Department of Neurology at University of California, Irvine. He is the Director of the UC Irvine-MDA ALS and Neuromuscular Center and the Director of the Division of Neuromuscular Disorders. From 2011-2017 he was the Program Director for the Neurology Residency Training Program and from 2017 - 2020, he was the interim chair of the Department of Neurology. He was the Chair of the Neuromuscular Section at the American Academy of Neurology from 2013-2015. He was the Chair of the Medical Advisory Board of the Myositis Association from 2013-2015. He currently serves as the Medical Board Liaison to the Board of Directors at the Myositis Association.
Additionally, Dr. Mozaffar serves as chair of one of the biomedical committees and the institutional liaison for Trials Innovation Hub for the Center for Translational Sciences Award (CTSA) at University of California, Irvine. He is the Principal Investigator for UCI-NEXT, the NeuroNEXT award to the University of California, Irvine, one of 25 such NeuroNEXT sites funded by the NINDS/NIH. He is also the Principal Investigator for INSPIRE-IBM, a multicenter NIH-funded natural history trial in Inclusion Body Myositis.
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Neuromuscular Medicine (Neurology), 1995 - 1997
- Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 1992 - 1995
- St Luke's HospitalInternship, Internal Medicine, 1991 - 1992
- Aga Khan Medical CollegeClass of 1989
- Adamjee Govt. Science CollegeH.Sc, Biology, 1981 - 1983
Certifications & Licensure
- CA State Medical License 1999 - 2025
- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- Best Doctors Best Doctors, 2015-2021
- Elected, Best Doctors Best Doctors, Inc., 2015
- Top Doctors:San Diego Area Castle Connolly, 2013
- Join now to see all
Clinical Trials
- Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Start of enrollment: 2006 Jun 01
- Trial on the Effect of Optically Modified Fiber Mattress Covers on Sleep Disturbances in Patients With Chronic Back Pain Start of enrollment: 2009 Jun 01
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Join now to see all
Publications & Presentations
PubMed
- 494 citationsEfficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trialPaul H. Gordon, Dan H. Moore, Robert G. Miller, Julaine Florence, Joseph L. Verheijde
The Lancet. Neurology. 2007-12-01 - 41 citationsSafety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-rand...Volkan Granit, Michael Benatar, Metin Kurtoglu, Miloš D Miljković, Nizar Chahin
The Lancet. Neurology. 2023-07-01 - 45 citationsA randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis.Merit E Cudkowicz, Stacy R Lindborg, Namita A Goyal, Robert G Miller, Matthew J Burford
Muscle & Nerve. 2022-03-01
Journal Articles
- 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016Allenbach Y, Mammen AL, Benveniste O, Stenzel W; Immune-Mediated Necrotizing Myopathies Working Group, Neuromuscul Disord, 1/1/2018
- Randomized study of adjunctive belimumab in participants with generalized myasthenia gravisHewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V; BEL115123 Study Group, Neurology, 1/1/2018
- A cross-sectional analysis of clinical evaluation in35 individuals with mutations of the valosin-containing protein genePlewa J, Surampalli A, Wencel M, Milad M, Donkervoort S, Caiozzo VJ, Goyal N, Mozaffar T, Kimonis V, Neuromuscul Disord, 1/1/2018
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Results from the MGTX Extension Study of thymectomy in myasthenia gravis.Wolfe G., Kaminski H., Aban I., Cutter G., MGTX Study Group, Muscle Nerve, 1/1/2018
- Results of an Investigator-Initiated Multi-Site LateOnset Pompe Disease Screening Study.Wencel M, Goyal N, Shaibani A, Dimachkie M, Johnson N, Trivedi J, Gutmann L, Wicklund M, Bandyopadhyay S, Genge A, Freimer M, Pestronk A, Florence J, Karam C, Ralph J,..., Ann Neurol, 1/1/2018
- Feasibility and validation of modified Oculobulbar facial respiratory score (mOBFRS) in sporadic inclusion body myositis.Wencel M, Araujo N, Medina E, Zhang LS, Nguyen D, Mozaffar T, Goyal N, Ann Neurol, 1/1/2018
- Join now to see all
Lectures
- Therapeutic Advances in Myasthenia GravisMontreal Neurological Institute, Montreal, CA - 1/1/2018
- Update on Idiopathic Inflammatory Myopathies: Diagnosis and TreatmentDallas, TX - 1/1/2018
- Utility of Genetic Testing in Neuromuscular DisordersVienna, Austria - 1/1/2018
- Join now to see all
Press Mentions
- AAN 2023: AT-GAA Motor Function Gains Now Seen for 4 Years in PompeMay 4th, 2023
- Cartesian Therapeutics Announces Dosing of First Participant in a Phase 2B Randomized Clinical Trial for Generalized Myasthenia GravisJanuary 31st, 2023
- Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe DiseaseFebruary 7th, 2022
- Join now to see all
Grant Support
- A Multicenter Study For The Validation Of ALS BiomarkersNational Center For Research Resources2010
- OPEN Label Extension Of Protocol Aals-001 (#Aals-001-Ol) - Arimoclomol In AMYNational Center For Research Resources2007–2008
- Combination Drug Selection Trial In Amyotrophic Lateral SclerosisNational Center For Research Resources2007–2008
- A Multi-Center, Phase III, Randomized, Double Blind, Placebo-Controlled, ClinicNational Center For Research Resources2006–2008
- Resequencing The Variable Human Genome In Sporadic ALS: A Necessary Prelude ToNational Center For Research Resources2007
- Amyotrophic Lateral Sclerosis Research Group [Als Rg] Collection Of Data And BINational Center For Research Resources2007
- A Multicenter, Dose Ranging Safety And Pharmacokinetics Study Of Arimoclomol In)National Center For Research Resources2006–2007
Professional Memberships
- Fellow
- American Neurological AssociationFellow
- World Muscle SocietyMember
- Muscle Study GroupMember, Executive Committee
Other Languages
- Hindi, Punjabi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: